A Phase I Study of Ridaforolimus in Pediatric Patients With Advanced Solid Tumors

Trial Profile

A Phase I Study of Ridaforolimus in Pediatric Patients With Advanced Solid Tumors

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 11 Apr 2017

At a glance

  • Drugs Ridaforolimus (Primary)
  • Indications Lymphoma; Solid tumours
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 05 Apr 2017 Planned End Date changed from 1 Mar 2017 to 21 Sep 2017.
    • 01 Sep 2016 Planned End Date changed from 1 Aug 2016 to 1 Mar 2017.
    • 24 Feb 2016 Planned End Date changed from 1 Feb 2016 to 1 Aug 2016, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top